Antiangiogenic antithrombin

Area of Science:

• Biochemistry
• Oncology
• Vascular Biology

Background:

• Angiogenesis is crucial in physiological and pathological processes, with inhibitors under investigation for cancer therapy.
• Antithrombin, a serpin, typically inhibits thrombin and clotting cascade enzymes.
• Tumor growth is influenced by various biological factors, including angiogenesis.

Purpose of the Study:

• To investigate the antiangiogenic and antitumor properties of antithrombin.
• To explore the potential of specific antithrombin conformations in cancer treatment.
• To elucidate the relationship between coagulation pathways and angiogenesis regulation.

Main Methods:

• Studied inhibition of tumor growth in a human small cell lung cancer model.
• Examined the antiangiogenic activity of cleaved, locked, and latent forms of antithrombin.
• Assessed the effects on endothelial cells and tumor vasculature in vivo.

Main Results:

• The cleaved conformation of antithrombin exhibited significant antiangiogenic and antitumor activity.
• Stable locked and latent forms of intact antithrombin also inhibited angiogenesis and tumor growth.
• Intact native antithrombin did not display these antiangiogenic effects.
• The antiangiogenic effects were selective for endothelial cells and tumor vasculature.

Conclusions:

• Specific conformations of antithrombin possess potent antiangiogenic and antitumor properties.
• This finding supports the connection between clotting/fibrinolytic pathways and angiogenesis.
• Antiangiogenic antithrombin may target endothelial cells to block the angiogenic cascade, offering a novel therapeutic strategy.